ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2020
Last Updated on 01 Apr 2020
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing vonoprazan on the Medication Assistance Fund (MAF) for treating Helicobacter pylori infection due to low clinical need, uncertain clinical effectiveness and unfavourable cost-effectiveness compared to alternate treatment options.

Vonoprazan for H pylori infection (1 Apr 2020) Vonoprazan for H pylori infection PES (1 Apr 2020)